RxDoctor Payments Data

Edward Freccero, MD

Internal Medicine · Brockton, MANPI 1679665442

Payments from drug & device makers

$138in general payments, 2019–2025

Across 9 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$36
  • AbbVie$29
  • Merck$29
  • AstraZeneca$17
  • Amneal Pharmaceuticals LLC$15
  • Pfizer$12

What the payments were for

  • Food & beverage$138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk2$36
AbbVie2$29
Merck2$29
AstraZeneca1$17
Amneal Pharmaceuticals LLC1$15
Pfizer1$12

How this compares

$138 in reported general payments places this provider in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$195,196
Medicare patients
362
Services billed
2,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$138,704
TrulicityDulaglutide78$96,734
XareltoRivaroxaban24$23,371
FarxigaDapagliflozin Propanediol17$19,637
OzempicSemaglutide13$12,761
LinzessLinaclotide14$9,748
Incruse ElliptaUmeclidinium Bromide15$6,966
Breo ElliptaFluticasone/Vilanterol17$6,936
Atorvastatin Calcium475$6,247
Duloxetine Hcl96$5,987
Sildenafil Citrate17$4,941
Metoprolol Succinate233$4,418
Pantoprazole Sodium272$4,330
Ezetimibe43$3,514
Celecoxib46$2,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$138,704129 claims
AstraZenecaFarxiga$17$19,63717 claims
Novo NordiskOzempic$36$12,76113 claims
AbbVieLinzess$29$9,74814 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,460277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →